concept

P-TAU

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about P-TAU: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

30Connections

21Hypotheses

0Analyses

6Outgoing

24Incoming

0Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	P-TAU
Key Genes/Proteins	APOE, ATG5
Related Diseases	ALZHEIMER, APOPTOSIS, AUTOPHAGY, CSF, NEURODEGENERATION
Related Pathways	INSULIN SIGNALING

Pathway Diagram

graph TD
    P_TAU[P-TAU]
    P_TAU -.prevents.-> neuronal_death[neuronal death]
    P_TAU -->|activates| NEURODEGENERATION[NEURODEGENERATION]
    P_TAU -.biomarker for.-> ALZHEIMER[ALZHEIMER]
    P_TAU -->|activates| APOPTOSIS[APOPTOSIS]
    quinic_acid[quinic acid] -->|decreases| P_TAU
    APOE[APOE] -->|produces| P_TAU
    TAU[TAU] -->|phosphorylates| P_TAU
    ATG5[ATG5] -->|degrades| P_TAU
    AUTOPHAGY[AUTOPHAGY] -->|exacerbates| P_TAU
    CSF[CSF] -->|synergizes_with| P_TAU

Outgoing (6)

Target	Relation	Type	Str
neuronal death	prevents	phenotype	0.93
Amyloid-Beta Pathophysiology	associated_with	process	0.85
NEURODEGENERATION	activates	phenotype	0.70
APOPTOSIS	activates	phenotype	0.65
NEURODEGENERATION	interacts_with	phenotype	0.65
ALZHEIMER	biomarker_for	disease	0.65

Incoming (24)

Source	Relation	Type	Str
37777806	exhibits pathological synergy with	paper	0.90
ALZHEIMER DISEASE	markers	gene	0.90
quinic acid	decreases	compound	0.80
APOE	produces	gene	0.70
TAU	phosphorylates	protein	0.65
AUTOPHAGY	exacerbates	phenotype	0.65
ATG5	inhibits	gene	0.65
ATG5	activates	gene	0.65
ATG5	treats	gene	0.65
ATG5	degrades	gene	0.65
CSF	associated_with	phenotype	0.60
AUTOPHAGY	implicated_in	phenotype	0.55
EXOSOME	associated_with	organelle	0.50
TREHALOSE	associated_with	drug	0.50
HIPPOCAMPUS	associated_with	brain_region	0.50
FDG-PET	associated_with	biomarker	0.50
INSULIN SIGNALING	associated_with	pathway	0.50
ENTORHINAL CORTEX	associated_with	brain_region	0.50
CORTEX	associated_with	brain_region	0.50
TEMPORAL LOBE	associated_with	brain_region	0.45
RAPAMYCIN	associated_with	drug	0.45
GLIAL FIBRILLARY ACIDIC PROTEIN	associated_with	biomarker	0.45
NEUROFILAMENT LIGHT	associated_with	biomarker	0.45
METFORMIN	associated_with	drug	0.45

Targeting Hypotheses (21)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Temporal Decoupling of CSF p-tau217 Normalization from Amylo	0.595	neurodegeneration	-
CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Patho	0.586	neurodegeneration	-
Residual Vascular Amyloid Prevents Complete CSF p-tau217 Nor	0.585	-	Can CSF p-tau217 normalization serve as
CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET N	0.565	-	Can CSF p-tau217 normalization serve as
HBOT (2.0 ATA, 60 min) activates TFEB-mediated autophagy-lys	0.560	neurodegeneration	What are the optimal oxygen pressure, du

Gamma-Entrained PV Interneuron Networks Enable Precision p-t	0.550	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Gamma-Entrained PV Interneurons Enable p-tau217-Guided Preci	0.547	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Combined p-tau217 + p-tau231 Panel Increases Specificity for	0.546	neurodegeneration	-
Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extrac	0.542	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Microglial Reactivation Status Modifies Amyloid Clearance an	0.524	neurodegeneration	-
CSF p-tau217 Normalization Requires Intact Synaptic Function	0.515	neurodegeneration	-
CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clini	0.512	neurodegeneration	-
Neurogranulin Predicts p-tau217 Reliability by Identifying P	0.498	neurodegeneration	-
Amyloid Plaque Clearance Triggers Downstream Reduction in Ta	0.475	-	Can CSF p-tau217 normalization serve as
Gamma-Entrained PV Interneurons Enable Precision p-tau217-Gu	0.464	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-	0.431	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
Neurogranin Co-Normalization Validates p-tau217 as a Surroga	0.415	-	Can CSF p-tau217 normalization serve as
Axonal Integrity Recovery Following Amyloid Clearance Drives	0.365	-	Can CSF p-tau217 normalization serve as
Individual Baseline Variability in p-tau217 Half-Life Dictat	0.335	-	Can CSF p-tau217 normalization serve as
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00	0.323	molecular-neurobiology	How does lncRNA-0021 achieve sequence-sp
P-tau217 Isoform Shift Indicates Mechanistic Transition Poin	0.245	-	Can CSF p-tau217 normalization serve as

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning P-TAU in their description or question text

Gamma-Entrained PV Interneuron Networks Enable Precision p-tau217-Guided lncRNA

Score: 0.550 · molecular-neurobiology · 2026-04-20

## Mechanistic Overview Gamma-Entrained PV Interneuron Networks Enable Precision p-tau217-Guided lncRNA Exosome Therapy

Gamma-Entrained PV Interneurons Enable p-tau217-Guided Precision Dosing of lncRN

Score: 0.547 · molecular-neurobiology · 2026-04-17

## Mechanistic Overview Gamma-Entrained PV Interneurons Enable p-tau217-Guided Precision Dosing of lncRNA Therapeutics i

Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Deli

Score: 0.542 · molecular-neurobiology · 2026-04-17

## Mechanistic Overview Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0

Amyloid Plaque Clearance Triggers Downstream Reduction in Tau Kinase Activity, N

Score: 0.475 · unknown disease · 2026-04-26

Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, which diminishes the path

Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome

Score: 0.464 · molecular-neurobiology · 2026-04-21

## Mechanistic Overview Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome Therapy in Early

Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy

Score: 0.431 · molecular-neurobiology · 2026-04-21

## Mechanistic Overview Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy Precision in Ea

Neurogranin Co-Normalization Validates p-tau217 as a Surrogate for Synaptic Heal

Score: 0.415 · unknown disease · 2026-04-26

CSF p-tau217 normalization must co-occur with neurogranin (Ng) stabilization to confirm cessation thresholds. Ng reflect

Axonal Integrity Recovery Following Amyloid Clearance Drives CSF p-tau217 Normal

Score: 0.365 · unknown disease · 2026-04-26

Donanemab treatment reduces amyloid-induced axonal transport deficits and endosomal trafficking impairment. Restored axo

Individual Baseline Variability in p-tau217 Half-Life Dictates Cessation Thresho

Score: 0.335 · unknown disease · 2026-04-26

CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter

Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Windo

Score: 0.323 · molecular-neurobiology · 2026-04-17

## Mechanistic Overview Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD starts f